Vaxcyte Inc is a biotechnology company focused on developing innovative vaccines to address significant infectious diseases
The company's research and development efforts center on utilizing its proprietary technology platform to design and produce a new generation of polysaccharide-based vaccines. By targeting a range of pathogens, Vaxcyte aims to enhance immune response and provide effective prevention measures against diseases that disproportionately affect public health. Through its work, the company seeks to contribute to a healthier global population by advancing the science of vaccinology.
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's Prevnar 20. VAX-31 will advance to Phase 3 trials with plans for a pivotal study by mid-2025.
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQPCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is upon us, yet the S&P 500 has been largely stagnant in recent trading sessions.
